LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global colorectal cancer therapeutics market since 2015, and the market is poised to grow by USD 994.94 million during 2019-2023, progressing at a CAGR of almost 3% during the forecast period. Request free sample pages
Read the 126-page report with TOC on “Colorectal Cancer Therapeutics Market Analysis Report by Type (targeted therapy, immunotherapy, and chemotherapy), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023”.
https://www.technavio.com/report/global-colorectal-cancer-therapeutics-market-industry-analysis
The introduction of combination therapy and the development of small molecule kinase inhibitors is anticipated to boost the growth of the colorectal cancer therapeutics market.
Combining two or more monotherapy drugs helps in overcoming the various limitations of each therapeutic. This results in the improvement of the efficacy of medications in treating colorectal cancer. For instance, FOLFRI-bevacizumab contains bevacizumab that inhibits vascular endothelial growth factor-specific angiogenesis and 5-fluorouracil that inhibits thymidylate synthase (TS), which is crucial in the synthesis of pyrimidine thymide, a nucleotide essential for the replication of DNA in cancer cells. The introduction of many such combination therapies for colorectal cancer treatment will have a positive impact on the growth of the market during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Colorectal Cancer Therapeutics Market Companies:
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates its business through the BioPharmaceuticals segment. The segment is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines. OPDIVO and YERVOY are some of the key offerings of the company.
Eli Lilly and Company
Eli Lilly and Company operates its business through segments such as Human pharmaceutical products and Animal health products. CYRAMZA and ERBITUX are some of the key products offered by the company.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd operates its business through segments such as Pharmaceuticals and Diagnostics. AVASTIN and XELODA are the key product offerings of the company.
Merck & Co., Inc.
Merck & Co., Inc. operates its business through segments such as Pharmaceutical and Other. KEYTRUDA is the key offering of the company.
Sanofi
Sanofi operates its business through segments such as Pharmaceuticals, Consumer Healthcare, and Vaccines. ELOXATIN and ZALTRAP are the key product offerings of the company.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Technavio has segmented the colorectal cancer therapeutics market based on the type and region.
Colorectal Cancer Therapeutics Type Outlook (Revenue, USD Million, 2019 - 2023)
- Targeted therapy
- Immunotherapy
- Chemotherapy
Colorectal Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)
- Asia
- Europe
- North America
- ROW
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare are:
Global Fallopian Tube Cancer Therapeutics Market – Global fallopian tube cancer therapeutics market by product (targeted therapy and chemotherapy) and geography (Asia, Europe, North America, and ROW).
Global Blood Cancer Therapeutics Market – Global blood cancer therapeutics market by type (leukemia, lymphoma, and myeloma) and geography (Asia, Europe, North America, and ROW).
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com
